Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS.
To comprehensively assess the safety of Lifitegrast, a drug for dry eye disease, we conducted a comprehensive analysis of adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS). This retrospective study examined all AE reports submitted between Q3 2016 and Q2 2024, employing...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0321307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|